SCHEMBL2270108

SCHEMBL2270108

O=C(Nc1cc(OC2CCCCC2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
PKM P14618 3/20 0.52
MAPT P10636 2/20 0.52
GRIK1 P39086 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
PDE5A O76074 2/20 0.48
PYGL P06737 1/20 0.48
PYGM P11217 1/20 0.48
KAT6A Q92794 1/20 0.47
MAOB P27338 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4D Q6B0I6 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KCNK2 O95069 1/20 0.46
KCNK10 P57789 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270244 0.90 PDE5A (0.58) MEN1KMT2AMAPTTDP1PDE5A
SCHEMBL8039707 0.83 MEN1 (0.55) MEN1KMT2APDE5ANPC1RAB9A
SCHEMBL2271588 0.78 SERPINE1 (0.64) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2935687 0.78 MEN1 (0.69) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2272370 0.77 SERPINE1 (0.59) MEN1KMT2APKMMAPTGRIK1
SCHEMBL28481347 0.77 MAOB (0.59) MAOBALDH1A1
SCHEMBL1466054 0.77 SMN1; SMN2 (0.52) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4210521 0.75 AKR1C3 (0.52) MAOB
SCHEMBL1376229 0.74 MAOB (0.56) MAPTKAT6AMAOBALDH1A1
SCHEMBL9002504 0.74 HPGD (0.59) MEN1KMT2AMAPTPDE5AKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.